Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Neurocrine Biosciences Inc (NBIX) vs Clear Secure Inc (YOU) Price & Performance

Neurocrine Biosciences IncTrade
Clear Secure IncTrade

Price performance (Past 24H)

Key statistics

Neurocrine Biosciences Inc vs Clear Secure Inc — how do they compare? Neurocrine Biosciences Inc trades at $179 (market cap $17.40B), while Clear Secure Inc trades at $57.03 (market cap $5.76B). The key difference: Neurocrine Biosciences Inc is far larger — about 3× Clear Secure Inc's market cap, and Clear Secure Inc pays a 1.05% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.

NBIXYOU
Market Cap
$17.40B$5.76B
Sector
HealthTechnology
52-Week High
$180.55$62.36
52-Week Low
$123.10$28.84
Enterprise Value
$16.49B$5.07B
Dividend Yield
1.05%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Neurocrine Biosciences Inc

Neurocrine Biosciences (NBIX) trades at $173.00, up 1.24% today, with strong technical momentum and bullish moving averages. The company demonstrates robust fundamentals with Q1 2026 EPS of $1.94 beating expectations by 59%, revenue growth to $3.1B in 2026, and net income margin expanding to 21.55%. Recent news highlights executive appointments and positive clinical trial updates for crinecerfont, supporting growth prospects.

Outlook remains positive with 86% analyst buy ratings and a $196.08 consensus price target implying 13% upside. Key risks include execution of pipeline developments and integration of acquisitions. The stock's valuation at P/E 26.62 appears reasonable given earnings growth trajectory and strong profitability metrics.

Clear Secure Inc

Clear Secure (YOU) trades at $57.18, up 2.05% with a bullish technical outlook. The stock shows strong profitability with 65.48% gross margins and 81.15% ROE, though valuation multiples appear elevated with a P/E of 45.74. Recent earnings beat expectations in Q1 2026 with $0.38 EPS versus $0.35 expected. The company continues expanding airport partnerships and launched AWS integration for contact center verification in June 2026.

Growth prospects remain positive with revenue projected to reach $942 million in 2026, but high valuation multiples and mixed analyst ratings (44% Buy, 44% Hold) suggest cautious optimism. Key risks include execution of expansion plans and competitive pressures in identity verification markets. The consensus price target of $56.67 offers limited upside from current levels.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Neurocrine Biosciences Inc

Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.

Read more on NBIX

About Clear Secure Inc

Clear Secure operates a secure identity platform that uses biometrics—specifically eyes, face, and fingerprints—to automate and expedite identity verification. While its most visible application is the CLEAR Plus airport subscription service, the company functions as a broad-based identity layer for travel, healthcare, and digital services, aiming to replace physical IDs with a secure, biometric link.

Read more on YOU